Key facts
- It has raised $7.7M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Shaanxi Growth Enterprise Guide Fund, Caleb Capital, Cybernaut (China) Investment, MPC (Beijing), Sundoc — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Polymed Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Polymed Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Polymed Biopharmaceuticals
Operator of a biopharmaceutical company intended to focus on novel therapies in the areas of oncology and autoimmune diseases. The company is committed to creating innovative medicines for treating patients using advanced technology platforms, including artificial intelligence and structural biology, and the approaches it uses include traditional protein inhibition and modern protein degradation, serving patients to fight autoimmune diseases and resist decay.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2018
- Employees
- 11
- Website
- polymedbiopharma.com/
- Ownership
- Privately Held (backing)
Polymed Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Polymed Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Polymed Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.